Skip to main content
SpringerLink
Log in

Drug-induced hypohidrosis and anhidrosis: analysis of the WHO pharmacovigilance database 2000–2020

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cheshire Jr WP, Fealey RD (2008) Drug-induced hyperhidrosis and hypohidrosis. incidence, prevention and management. Drug Safety 31:109–126

  2. Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE (2020) Uses of pharmacovigilance databases: an overview. Therapie 75:591–8

  3. Moore N, Berdaï D, Blin P, Droz C (2019) Pharmacovigilance - the next chapter. Therapie 74:557–567

    Article  Google Scholar 

  4. Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R (2019) The French Levothyrox® crisis: We did the best we could but… Therapie 74:431–435

  5. Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905–908

    Article  CAS  Google Scholar 

  6. Faillie JL (2019) Case-non-case studies: principle, methods, bias and interpretation. Therapie 74:225–232

    Article  Google Scholar 

  7. Brown JH, Brandi K, Wess J (2018) Muscarinic receptor agonists and antagonists. In: Bruton LL, Hilal-Dandan R, Knollman BC (eds) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Mc Graw Hill Editions, New York, pp 149–162

  8. Delort S, Marchi E, Corrêa MA (2017) Oxybutynin as an alternative treatment for hyperhidrosis. An Bras Dermatol 92:217–220

    Article  Google Scholar 

  9. Cruddas L, Baker DM (2017) Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol 31:952–963

    Article  CAS  Google Scholar 

  10. Incecik F, Hergüner MO, Altunbaşak S (2012) Hypohidrosis and hyperthermia during topiramate treatment in children. Turk J Pediatr 54:515–518

    PubMed  Google Scholar 

  11. Karachristianou S, Papamichalis E, Sarantopoulos A, Boura P, Georgiadis G (2013) Hypohidrosis induced by topiramate in an adult patient. Epileptic Disord 15:203–206

    Article  Google Scholar 

  12. Franco V, Barbieri MA, Cutroneo PM, Arena I, Cicala G, Marchione P, Spina E, Perucca E (2021) Pediatric adverse reactions to antiseizure medications - an analysis of data from the Italian spontaneous reporting system (2001–2019). Epilepsy Behav 119:107989. https://doi.org/10.1016/j.yebeh.2021.107989 (Epub 2021 May 1)

    Article  PubMed  Google Scholar 

  13. Smith MD, MetcalfCS, Wicox KS (2018) Pharmacotherapy of the epilepsies. In: LL Brunton, Hilal-Dandan R, Knollmann BC (eds) Goodman and Giman’s The Pharmacological Basis of Therapeutics, 13th edn. Mac Graw Hill. New York, pp 3003–326

  14. Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E and the French Network of Pharmacovigilance Centres (2021) Adverse drug reactions profiles for abiraterone and enzalutamide: a pharmacovigilance descriptive analysis. Therapie 76:455–465

  15. Villier C, Mallaret MP (2002) Nefopam abuse. Ann Pharmacother 36:1564–1566

    Article  Google Scholar 

  16. Revol B, Delorme J, Jouanjus É, Spadari M, Djezzar S, Lepelley M, Khouri C, Fouilhé Sam-Laï N, Mallaret M (2021) le réseau français des Centres d’addictovigilance. Thirty years of nefopam abuse in France. Therapie 76:527–537

  17. Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski JL (2021) Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol 134:14–21

    Article  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the Uppsala Monitoring Centre (UMC) that provided and gave permission to use the data analysed in the present study. The authors are indebted to the National Pharmacovigilance Centres that contributed data. Vigibase® is freely available in our department. According to the French clinical research law, review by an ethics committee and patients’ informed consent is not required for such studies. The opinions and conclusions in this study are not necessarily those of the various centres or of the WHO or ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé, France).

Funding

The work was performed during the university research time of the authors using the database, which is available without fees in the department of the authors. There were no funding sources. The authors certify that they have not received any funding from any institution, including personal relationships, interests, grants, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, stock options/ownership or expert testimony.

Author information

Authors and Affiliations

  1. Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d’Informations sur Le Médicament, Faculté de Médecine, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse, France

    Jean-Louis Montastruc & Geneviève Durrieu

Authors
  1. Jean-Louis Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geneviève Durrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JLM designed the study, extracted the data from the database and performed the statistical analysis. JLM and GD analysed and discussed the data. JLM wrote the paper. JLM and GD reviewed the successive versions of the manuscript and approved the final version.

Corresponding author

Correspondence to Jean-Louis Montastruc.

Ethics declarations

Ethics approval

According to the clinical research French law, review from an ethics committee is not required for such observational studies. As all data from VigiBase were deidentified, patient informed consent was not necessary. The authors are willing to share source data as requested.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Montastruc, JL., Durrieu, G. Drug-induced hypohidrosis and anhidrosis: analysis of the WHO pharmacovigilance database 2000–2020. Eur J Clin Pharmacol 78, 887–889 (2022). https://doi.org/10.1007/s00228-021-03268-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03268-w

Search

Navigation